Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer

被引：0
|
作者：
Wu, Xue
Zhang, Yaru
Pang, Jiaohui
Lin, Li
Yin, Jiani C.
Tang, Haimeng
Shao, Yang
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-940
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
940
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.
    Minne, Rachel
    Luo, Natalie
    Traynor, Anne M.
    Huang, Minxuan
    De Tullio, Luisina
    Godden, Jen
    Stoppler, Melissa Conrad
    Kimple, Randall J.
    Baschnagel, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC)
    Marks, Jennifer Aline
    Gandhi, Nishant
    Halmos, Balazs
    Ramalingam, Suresh S.
    Bazhenova, Lyudmila
    Marmarelis, Melina Elpi
    Xiu, Joanne
    Walker, Phillip
    Oberley, Matthew James
    Ma, Patrick C.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non -small cell lung cancer?
    Pruis, Melinda A.
    von der Thusen, Jan H.
    Dubbink, Hendrikus Jan
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (22)
  • [24] Characterization of MET Exon 14 Skipping Analog (Y1003) in Non-Small Cell Lung Cancer (NSCLC)
    Kim, S. Y.
    Narvel, H. G.
    Gandhi, N.
    Marks, J. A.
    Zaemes, J. P.
    Dacic, S.
    Liu, S. V.
    Kim, C.
    Ma, P. C.
    Reckamp, K.
    Feldman, R.
    Nagasaka, M.
    Khan, H.
    Uprety, D.
    Xiu, J.
    Vanderwalde, A.
    Cheng, H.
    Halmos, B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S210 - S211
  • [25] Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies
    Wu, Yi-Long
    Smit, Egbert F.
    Bauer, Todd M.
    CANCER TREATMENT REVIEWS, 2021, 95
  • [26] Analysis of MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC) by histology and specific mutation.
    Marks, Jennifer Aline
    Yin, Jun
    Halmos, Balazs
    Bazhenova, Lyudmila
    Ramalingam, Suresh S.
    Marmarelis, Melina Elpi
    Xiu, Joanne
    Walker, Phillip
    Oberley, Matthew James
    Ma, Patrick C.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
    Zheng, Difan
    Wang, Rui
    Ye, Ting
    Yu, Su
    Hu, Haichuan
    Shen, Xuxia
    Li, Yuan
    Ji, Hongbin
    Sun, Yihua
    Chen, Haiquan
    ONCOTARGET, 2016, 7 (27) : 41691 - 41702
  • [28] Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
    Brazel, Danielle
    Zhang, Shannon
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 33 - 45
  • [29] Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress
    Paik, P.
    Sakai, H.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1046 - S1046
  • [30] Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Zhang, Eric W.
    Lennerz, Jochen K.
    Heist, Rebecca S.
    CANCERS, 2019, 11 (12)
12345